Engineered immune cells take on Hard-to-Treat cancers in early trial

NCT ID NCT04119024

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 32 times

Summary

This early-phase study tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dose and to see if the cells can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

    Contact Email: •••••@•••••

    Contact

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 93405, United States

    Contact

    Contact Email: •••••@•••••

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.